Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).

doi:10.1016/j.jtho.2024.12.010

Article

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 May 2025

Passiglia Francesco, Listì Angela, Bironzo Paolo, Merlini Alessandra, Benso Federica, Napoli Francesca, Barbu Francesca Alice, Zambelli Vanessa, Tabbò Fabrizio, Reale Maria Lucia, Sini Claudio, Roca Elisa, Taveggia Paola Adriana, Simionato Francesca, Buffoni Lucio, Mazilu Laura, Barbieri Vito, Pignataro Daniele, Araujo Antonio, Paz-Ares Luis, Felip Enriqueta, Secen Nevena, Comanescu Alina, Ramizi Kleida Mati, Bettini Anna Cecilia, Scotti Vieri, Linardou Helena, Mohorcic Katja, Meoni Giulia, Giannarelli Diana, Volante Marco, Malapelle Umberto, Vallone Stefania, Scagliotti Giorgio, Righi Luisella, Novello Silvia

Abstract excerpt

INTRODUCTION: The advocacy Women Against Lung Cancer in Europe (WALCE) promoted the European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) and provided a free-of-charge molecular profiling platform for NSCLC sample characterization with the aim of increasing the detection of targetable drivers and improving patients' access to clinical trials in Europe. METHODS: From January 2021...

Topics

Join the communities discussing this publication.

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).

Abstract excerpt

Topics

Discuss the evidence

Related research